SKP-1041: Phase II started

SkyePharma began a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate oral 10, 15, and 20 mg SKP-1041 given before bedtime for 2 nights each followed by a 4-7 day washout per...